Yazarlar : Beveridge R, Satram-Hoang S, Sail K, Darragh J, Chen C, Forsyth M, Reyes C.

Yayın : Leuk Lymphoma.

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21745172

Konu : Lenfoma

Literatür İçeriği :  

Abstract

Abstract Using a retrospective claims database, we estimated the economic costs of progression among patients with follicular non-Hodgkin lymphoma (f-NHL) treated in an outpatient community-based setting. Patients with f-NHL who received care between 1 July 2006 and 31 December 2009 were categorized into two cohorts based on whether they experienced progressive disease (PD) or not. Costs per patient per month (PPPM) were compared between patients with PD versus non-PD. Follow-up time was censored at the last entry for disease status or 6 months after the date of remission/stable disease or progression. Of the 1002 patients with f-NHL identified, 268 progressed and 734 did not. The mean overall costs PPPM over the 6-month follow-up period were significantly higher for patients with PD versus non-PD ($3527 vs. $860; difference = $2667; p < 0.001). This cost difference persisted within all resource categories evaluated. Results of this study indicate that therapies which delay progression for patients with f-NHL may result in potential cost savings.

Literatür Arşivi